About 7,848 results

ALLMedicine™ Cholangitis Center

Research & Reviews  2,770 results

Immune-Mediated Diseases Associated With Cancer Risks.
JAMA Oncology; He MM, Lo CH et. al.

Dec 3rd, 2021 - Immune regulation is important for carcinogenesis; however, the cancer risk profiles associated with immune-mediated diseases need further characterization. To assess the prospective association of 48 immune-mediated diseases with the risk of tota...

QTc interval prolongation in the patients with primary biliary cholangitis.
Annals of Noninvasive Electrocardiology : the Official Jo... Wang Z, Qian R et. al.

Dec 3rd, 2021 - The QT interval prolongation was associated with fatal arrhythmias and cardiac death. However, there were not adequate data to clarify the situation of QT interval prolongation in primary biliary cholangitis (PBC) patients. The aim of this study w...

P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bow...
The American Journal of Gastroenterology; Varun J, Brian B et. al.

Dec 2nd, 2021 - P022 Biologic Therapy and Therapeutic Drug Monitoring in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.|2021|Varun J,Brian B,Esteban F,|

The feasibility of cap-assisted routine adult colonoscope for therapeutic ERCP in patie...
Journal of Digestive Diseases; Ni J, Zhu M et. al.

Nov 25th, 2021 - Endoscopic retrograde cholangiopancreatography (ERCP) in patients with Roux-en-Y (RY) reconstruction after total gastrectomy is difficult to be performed with routine instruments. The primary aim of this study was to analyze the feasibility and sa...

see more →

Guidelines  21 results

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.
Clinics and Research in Hepatology and Gastroenterology; Chazouillères O, Potier P et. al.

Aug 1st, 2021 - Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the biliary tree. A...

ASGE guideline on the management of cholangitis.
Gastrointestinal Endoscopy; Buxbaum JL, Buitrago C et. al.

May 24th, 2021 - Cholangitis is a GI emergency requiring prompt recognition and treatment. The purpose of this document from the American Society for Gastrointestinal Endoscopy's (ASGE) Standards of Practice Committee is to provide an evidence-based approach for m...

COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wa...
Journal of Crohn's & Colitis; Ng SC, Mak JWY et. al.

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  114 results

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Nov 24th, 2021 - The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Evaluation of Patients With Liver Disease

Nov 18th, 2021 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis

Nov 16th, 2021 - Decompensated cirrhosis has a high overall mortality rate. Liver transplantation is still the most effective treatment for decompensated cirrhosis. However, the shortage of matched liver sources, high costs, and rejection after liver transplantati...

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Nov 10th, 2021 - This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Nov 9th, 2021 - The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and inadequate response or intolerance to Ursode...

see more →

News  221 results

Partner Perspectives: Moving Cholangiocarcinoma Into the Age of Targeted Therapy

Oct 6th, 2021 - Biliary tract cancers are an aggressive group of malignancies that historically have been very challenging to treat because of their anatomical location and limited responsiveness to systemic therapy.1-3 Biliary cancers arise from the epithelial l...

Screen for Primary Sclerosing Cholangitis in IBD?

Sep 7th, 2021 - NEW YORK (Reuters Health) - About 2% of patients with inflammatory bowel diseases (IBD) will develop primary sclerosing cholangitis (PSC), with a higher prevalence in men than women, according to a new analysis. In a paper in Gastroenterology, the...

Several Risk Factors Tied to Fatal Post-Liver Transplant Infections

Aug 9th, 2021 - Fewer than half of liver transplant patients who developed invasive fungal infections (IFI) died after surgery, with several key factors contributing to mortality risk, researchers found in a small retrospective study. Out of 33 patients who devel...

FDA Restricts Ocaliva Use in Primary Biliary Cholangitis

May 27th, 2021 - FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects, such as liver failure or the urgent need for ...

FDA Restricts Obeticholic Acid (Ocaliva) Over Serious Liver Injury Risk

May 26th, 2021 - The risk for serious liver injury with obeticholic acid (Ocaliva, Intercept Pharmaceuticals) has prompted the US Food and Drug Administration (FDA) to restrict its use in patients with primary biliary cholangitis (PBC) and advanced cirrhosis.  The...

see more →

Patient Education  8 results see all →